文献速递系统性红斑狼疮

抗疟药与系统性红斑狼疮全因及病因特异性死亡率降低相关

Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于江苏狼疮数据库2446例SLE患者的前瞻性随访研究,共观察到221例死亡。与未使用者相比,HCQ或CQ使用者的全因死亡率调整风险比分别为0.49(95%CI 0.35–0.67)和0.49(95%CI 0.27–0.87)。HCQ/CQ使用时间及每日剂量与死亡率降低呈线性剂量反应关系,且与肾功能不全和其他器官受累相关死亡呈负相关。

要点

  • HCQ或CQ使用与SLE患者全因死亡率降低相关,调整HR均为0.49。
  • HCQ/CQ使用时间及每日剂量与死亡率降低呈线性剂量反应关系。
  • HCQ/CQ与肾功能不全及其他器官受累相关死亡呈负相关,但与感染和神经精神受累死亡无显著关联。

核心结论

  • 抗疟药与SLE患者较低的全因死亡风险相关,尤其是肾功能不全和其他器官受累相关死亡。
  • 坚持用药和足量用药可能增强抗疟药对生存的保护效应。

研究设计与样本

  • 从江苏狼疮数据库提取1999–2009年首次住院SLE患者的HCQ/CQ处方信息,并于2010年和2015年进行生存状态随访。
  • 共纳入2446例SLE患者,采用Cox模型和限制性立方样条模型估计风险比及95%CI。

主要发现

  • 共观察到221例死亡。
  • 与未使用者相比,HCQ使用者全因死亡率调整HR为0.49(95%CI 0.35–0.67),CQ使用者为0.49(95%CI 0.27–0.87)。
  • HCQ/CQ与全因死亡率的关联在合并症和器官受累等亚组中相似。
  • HCQ/CQ使用时间和每日剂量均与SLE死亡率降低呈线性剂量反应关系。
  • HCQ/CQ与肾功能不全相关死亡的调整HR为0.23(95%CI 0.09–0.55),与其他器官受累相关死亡的调整HR为0.25(95%CI 0.10–0.62);与感染和神经精神受累相关死亡无显著关联。

临床怎么用

  • 对SLE患者可考虑使用HCQ或CQ以降低死亡风险,尤其关注肾功能不全和其他器官受累相关死亡。
  • 临床应重视抗疟药的用药依从性和足量使用,以可能增强生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients. METHODS: Medical records including information on HCQ/chloroquine (CQ) prescription were extracted from Jiangsu Lupus database. The database was designed to collect data from SLE patients that first-hospitalized during 1999-2009 in Jiangsu province, China, and a follow-up for survival status was performed in 2010 and 2015. Cox and restricted cubic spline models were used to estimate the hazard ratio and 95% CI. RESULTS: We identified 221 deaths among 2446 SLE patients in total. Compared with non-users, decreased overall mortality was associated with either HCQ or CQ users, with adjusted hazard ratio (95% CI) of 0.49 (0.35, 0.67) and 0.49 (0.27, 0.87), respectively. The association between HCQ/CQ and overall mortality was similar across subgroups, such as patients with comorbidities and organ involvements. Interestingly, both the time and the daily dosage of HCQ/CQ use were related to decreased mortality of SLE in a linear dose-response relationship. In cause specific analyses, HCQ/CQ was inversely associated with death from renal insufficiency and other organ (cardiopulmonary, gastrointestinal and haematological) involvements, with adjusted hazard ratio (95% CI) of 0.23 (0.09, 0.55) and 0.25 (0.10, 0.62), respectively, yet it was not significantly associated with mortality from infection and neuropsychiatric involvements. CONCLUSION: Antimalarial drugs were associated with lower risk of SLE mortality, especially renal insufficiency- and other organ involvement-related death. The protective effects for survival might be augmented by adherence and full dosage of these drugs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jin Z, Wang F, Pan W, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33099642. doi:10.1093/rheumatology/keaa485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。